Latest Healthcare News

EBOS Group has fixed the dividend reinvestment price for its 2026 final distribution at NZD 20.47 per share, representing a 2% discount to the relevant NZX VWAP. The total payment remains NZD 0.63670588 per share, with cash distributions due on 18 September.

Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.

OncoSil Medical has secured $5.6 million from its three largest institutional investors to fund commercial launches of its OncoSil device in the United States and Australia. The commitments follow FDA and TGA approvals and would lift pro-forma cash to $12.1 million once completed.

Clever Culture Systems secures a follow-up order from Novo Nordisk for two APAS Independence instruments, marking a critical step toward broader global deployment and signalling expected sales growth from FY27.

EBR Systems has secured ISO 13485 certification for its new Santa Clara manufacturing site, paving the way for a 500% increase in WiSE System production pending FDA approval expected by year-end.

CONNEQT Health has inked a marketing deal with US longevity platform Blueprint to boost consumer sales of its FDA-cleared Pulse arterial health monitor, targeting health-conscious Americans focused on preventative care.

Avenira Limited (ASX: AEV) has pushed back the closing date of its $48.87 million renounceable rights issue by a week, responding to shareholder demand and expanding eligibility to overseas investors.

Actinogen Medical (ASX:ACW) has clarified that no undisclosed information explains recent unusual trading in its shares, pointing instead to recent underwriting of options and published updates. The biotech also reaffirmed compliance with ASX rules and provided a detailed update on its lead Alzheimer’s drug Xanamem and ongoing clinical trials.

Immuron Limited has inked an exclusive US distribution deal for PROIBS®, a European-certified medical device targeting abdominal discomfort, marking a key step in its digestive health portfolio growth.

Memphasys has secured product registration for its Felix™ System in Turkey, marking the start of commercial sales with an initial order of 100 cartridges and two consoles. The move taps into a large assisted-reproduction market with strong growth potential.

Cleo Diagnostics has received its first commercial batch of ovarian cancer test kits from Bio-Techne, marking the start of analytical validation critical for its FDA submission planned in early 2027.

EMVision is progressing its CRC-P funded Regional Benefits Study to evaluate the emu™ bedside brain scanner in remote hospitals, aiming to speed up stroke diagnosis where CT access is limited. Site visits are complete, and protocol development is underway, with relevance extending to similar rural hospitals in the US.